Shanghai Shen Lian Biomedical Corporation Lanzhou Branch is pleased to announce that it has successfully passed the veterinary drug GMP audit and has been granted both the Veterinary Drug GMP Certificate and the Veterinary Drug Production License by the Gansu Provincial Animal Husbandry and Veterinary Bureau.

Shenlian Biomedical has recently successfully passed the GMP inspection for its cell suspension cultured virus inactivated vaccine (including cell suspension cultured virus subunit vaccine) production line. This line can be used to produce inactivated vaccines for lumpy skin disease, porcine Seneca virus disease, porcine pseudorabies virus gene-deleted disease, and a trivalent inactivated vaccine against porcine infectious gastroenteritis, porcine epidemic diarrhea, and porcine deltacoronavirus disease.

The successful GMP certification signifies a significant expansion of Shenlian Biomedical's vaccine production capacity and scope. With a more diverse product range, the company can now offer a more comprehensive suite of products to a wider range of livestock farmers.

Taking this opportunity, Shenlian Biomedical will continue to upgrade its quality and product safety management systems. Through innovation and attention to detail, the company will continuously meet the higher-level demands of customers for products and services, contributing to the healthy and sustainable development of China's livestock industry.

In the future, Shenlian Biomedical will continue to uphold its commitment to quality and brand building, continuously supplying the market with high-quality products, providing dedicated customer service, and striving to build a world-class high-tech biopharmaceutical company.